Stéfan Halbherr is one of five founders of the start-up company InnoMedica and has led the Research and Development department since the beginning 4 years ago. He studied biochemistry and immunology and holds a PhD degree from the University of Berne (Switzerland).
With a dedicated team and a 22-people-strong company he aims at bridging the gap between innovative medicine and patient’s needs. He developed a unique industrial scale GMP manufacturing process for ultra-small liposomes with novel biological properties.
This process enabled the research of pipeline products that today cover the areas of nano-chemotherapy and image guided surgery in oncology, neurodegenerative diseases, and bacteriology. With the first product Talidox moving into phase 1 testing a major milestone has been achieved.
Liposome pipeline addressing unmet medical needs in oncology, imaging, and neurodegeneration
Ultra-small liposomes of 30nm in size give rise to unknown pharmacological effects. Talidox (Targeted Liposomal Doxorubicin) accumulates chemotherapeutic drug in cancer tissue and minimizes its side effects. Using the nano-shuttle, near-infrared dye is specifically transported to tumors and can assist during fluorescence-guided surgery. Talineuren (Targeted Liposomal Neuroregenerator) delivers neuroprotective GM1 ganglioside to the brain after oral intake, thereby e.g. elevating dopamine levels in the striatum in Parkinson models of disease.
EVEN MORE SEMINARS
Prof Adam Waldman MRC Institute of Genetics & Molecular Medicine CANCER RESEARCH UK Imaging
Biomarkers in Adult Glioma
Nirmesh Patel Cambridge Cancer Genomics
Monitoring cancer evolution through smart genomics and liquid biopsies
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients
Sam Janes UCL
Early Detection of Lung Cancer
Merina Ahmed Royal Marsden NHS foundation Trust
Stereotactic Radiotherapy for lung tumours and oligometastatic disease